

Sengwee Toh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4865995/publications.pdf>

Version: 2024-02-01

185
papers

5,819
citations

61984

43
h-index

98798

67
g-index

196
all docs

196
docs citations

196
times ranked

7446
citing authors

#	ARTICLE	IF	CITATIONS
1	Distributed Cox proportional hazards regression using summary-level information. <i>Biostatistics</i> , 2023, 24, 776-794.	1.5	4
2	Who gets treated for influenza: A surveillance study from the US Food and Drug Administration's Sentinel System. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1228-1234.	1.8	2
3	Use of Linked Databases for Improved Confounding Control: Considerations for Potential Selection Bias. <i>American Journal of Epidemiology</i> , 2022, , .	3.4	5
4	Validation of diagnosis codes to identify hospitalized COVID-19 patients in health care claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 476-480.	1.9	25
5	Antibiotics prior to age 2 years have limited association with preschool growth trajectory. <i>International Journal of Obesity</i> , 2022, 46, 843-850.	3.4	0
6	Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data. <i>American Journal of Epidemiology</i> , 2022, 191, 908-920.	3.4	2
7	Utility of fertility procedures and prenatal tests to estimate gestational age for live births and stillbirths in electronic health plan databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	1
8	Statin use is associated with lower risk of dementia in stroke patients: a community-based cohort study with inverse probability weighted marginal structural model analysis. <i>European Journal of Epidemiology</i> , 2022, 37, 615-627.	5.7	6
9	Continuity and Completeness of Electronic Health Record Data for Patients Treated With Oral Hypoglycemic Agents: Findings From Healthcare Delivery Systems in Taiwan. <i>Frontiers in Pharmacology</i> , 2022, 13, 845949.	3.5	2
10	Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1623-1637.	4.4	9
11	Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations. <i>Drug Safety</i> , 2022, 45, 493-510.	3.2	5
12	Profiling real-world data sources for pharmacoepidemiologic research: A call for papers. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 929-931.	1.9	1
13	Variance estimation in inverse probability weighted Cox models. <i>Biometrics</i> , 2021, 77, 1101-1117.	1.4	23
14	Building an active medical product safety surveillance system in Taiwan: Adaptation of the U.S. Sentinel System common data model structure to the National Health Insurance Research Database in Taiwan. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 97-101.	1.9	11
15	Risk of Psychiatric Adverse Events Among Montelukast Users. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 385-393.e12.	3.8	30
16	The Certainty Framework for Assessing Real-World Data in Studies of Medical Product Safety and Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1189-1196.	4.7	17
17	Early Life Antibiotic Prescriptions and Weight Outcomes in Children 10 Years of Age. <i>Academic Pediatrics</i> , 2021, 21, 297-303.	2.0	8
18	Estimating the marginal hazard ratio by simultaneously using a set of propensity score models: A multiply robust approach. <i>Statistics in Medicine</i> , 2021, 40, 1224-1242.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab009.	2.9	17
20	Electronic phenotyping of health outcomes of interest using a linked claims-electronic health record database: Findings from a machine learning pilot project. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 1507-1517.	4.4	15
21	A <sc>COVID</sc>-ready public health surveillance system: The Food and Drug Administration's Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 827-837.	1.9	26
22	Automatable Distributed Regression Analysis of Vertically Partitioned Data Facilitated by PopMedNet: Feasibility and Enhancement Study. <i>JMIR Medical Informatics</i> , 2021, 9, e21459.	2.6	1
23	Effect of <sc>ICD-9-CM</sc> to <sc>ICD-10-CM</sc> coding system transition on identification of common conditions: An interrupted time series analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1653-1674.	1.9	12
24	Prevalence of prescription opioid use during pregnancy in eight US health plans during 2001-2014. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1541-1550.	1.9	2
25	Association of Early Antibiotic Exposure With Childhood Body Mass Index Trajectory Milestones. <i>JAMA Network Open</i> , 2021, 4, e2116581.	5.9	13
26	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. <i>JAMA Internal Medicine</i> , 2021, 181, 1596-1604.	5.1	14
27	ppmHR. <i>Epidemiology</i> , 2021, 32, e6-e7.	2.7	0
28	Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework. <i>Npj Digital Medicine</i> , 2021, 4, 170.	10.9	25
29	Privacy-protecting multivariable-adjusted distributed regression analysis for multi-center pediatric study. <i>Pediatric Research</i> , 2020, 87, 1086-1092.	2.3	10
30	Use of Intrauterine Devices and Risk of Human Immunodeficiency Virus Acquisition Among Insured Women in the United States. <i>Clinical Infectious Diseases</i> , 2020, 70, 2221-2223.	5.8	0
31	Inverse probability weighted Cox model in multi-site studies without sharing individual-level data. <i>Statistical Methods in Medical Research</i> , 2020, 29, 1668-1681.	1.5	30
32	Reproducing Protocol-Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 966-977.	4.7	3
33	Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. <i>Epidemiology</i> , 2020, 31, 82-89.	2.7	9
34	Analytic and Data Sharing Options in Real-World Multidatabase Studies of Comparative Effectiveness and Safety of Medical Products. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 834-842.	4.7	13
35	Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 786-795.	1.9	9
36	Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. <i>Epidemiology</i> , 2020, 31, 806-814.	2.7	6

#	ARTICLE	IF	CITATIONS
37	Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2506-2516.	6.1	8
38	Validity of diagnosis and procedure codes for identifying neural tube defects in infants. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1489-1493.	1.9	0
39	Suitability of administrative claims databases for bariatric surgery research – is the glass half-full or half-empty?. <i>BMC Medical Research Methodology</i> , 2020, 20, 225.	3.1	5
40	Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. <i>JAMA Internal Medicine</i> , 2020, 180, 1587.	5.1	51
41	Conducting prospective sequential surveillance in real-world dynamic distributed databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1331-1335.	1.9	0
42	Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass. <i>JAMA Surgery</i> , 2020, 155, e200087.	4.3	138
43	Translating claims-based CHA ₂ DS ₂ -VaSc and HAS-BLED to ICD-10-CM: Impacts of mapping strategies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 409-418.	1.9	9
44	Interventions and Operations 5 Years After Bariatric Surgery in a Cohort From the US National Patient-Centered Clinical Research Network Bariatric Study. <i>JAMA Surgery</i> , 2020, 155, 194.	4.3	82
45	Use of real-world evidence in regulatory decisions for rare diseases in the United States – Current status and future directions. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1213-1218.	1.9	71
46	Trends in Dispensing of Zolpidem and Low-Dose Trazodone Among Commercially Insured Adults in the United States, 2011-2018. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2211.	7.4	19
47	Distributed Regression Analysis Application in Large Distributed Data Networks: Analysis of Precision and Operational Performance. <i>JMIR Medical Informatics</i> , 2020, 8, e15073.	2.6	5
48	Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 668-672.	0.9	0
49	Developing a Standardized and Reusable Method to Link Distributed Health Plan Databases to the National Death Index: Methods Development Study Protocol. <i>JMIR Research Protocols</i> , 2020, 9, e21811.	1.0	2
50	Translating stakeholder-driven comparative effectiveness research into practice: the PCORnet Bariatric Study. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1035-1041.	1.4	1
51	Identification of potential drug name confusion errors in the Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1405-1410.	1.9	0
52	Safe Expectations: Current State and Future Directions for Medication Safety in Pregnancy Research. <i>Clinical Therapeutics</i> , 2019, 41, 2467-2476.	2.5	11
53	Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. <i>Pharmaceutical Medicine</i> , 2019, 33, 29-43.	1.9	4
54	Maternal antibiotic use during pregnancy and childhood obesity at age 5 years. <i>International Journal of Obesity</i> , 2019, 43, 1202-1209.	3.4	23

#	ARTICLE	IF	CITATIONS
55	Sound-Alike Look-Alike Confusion and Matching Medication Product Attributes: Simulated Case-Control Studies. <i>Annals of Pharmacotherapy</i> , 2019, 53, 973-980.	1.9	1
56	Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching—a plasmode simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 879-886.	1.9	4
57	The Devil's in the details: Reports on reproducibility in pharmacoepidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 671-679.	1.9	5
58	Use of Antidiabetic drugs during pregnancy among U.S. women with Livebirth deliveries in the Mini-Sentinel system. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 441.	2.4	6
59	Privacy-protecting estimation of adjusted risk ratios using modified Poisson regression in multi-center studies. <i>BMC Medical Research Methodology</i> , 2019, 19, 228.	3.1	4
60	Use of tumor necrosis factor- α inhibitors during pregnancy among women who delivered live born infants. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 296-304.	1.9	15
61	Diagnostic Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review. <i>Drug Safety</i> , 2019, 42, 515-527.	3.2	12
62	Misclassification in Assessment of First Trimester In-utero Exposure to Drugs Used Proximally to Conception: the Example of Letrozole Utilization for Infertility Treatment. <i>American Journal of Epidemiology</i> , 2019, 188, 418-425.	3.4	10
63	Pregnancy-Associated Cancer: A U.S. Population-Based Study. <i>Journal of Women's Health</i> , 2019, 28, 250-257.	3.3	87
64	Validity of Privacy-Protecting Analytical Methods That Use Only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data Networks. <i>American Journal of Epidemiology</i> , 2019, 188, 709-723.	3.4	25
65	Antipsychotic Use and Stroke. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	8
66	Comparing Prescribing and Dispensing Data of the PCORnet Common Data Model Within PCORnet Antibiotics and Childhood Growth Study. <i>EGEMS (Washington, DC)</i> , 2019, 7, 11.	2.0	9
67	Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. <i>EGEMS (Washington, DC)</i> , 2019, 7, 27.	2.0	2
68	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 707-712.	1.9	7
69	Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1045-1056.	2.4	9
70	Utilization of drugs with pregnancy exposure registries during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 604-611.	1.9	11
71	Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis. <i>Medical Care</i> , 2018, 56, 365-372.	2.4	9
72	Lower Cancer Incidence—Warfarin Effect or Immortal Time Bias?. <i>JAMA Internal Medicine</i> , 2018, 178, 584.	5.1	3

#	ARTICLE	IF	CITATIONS
73	The impact of FDA regulatory activities on incident dispensing of LABA-containing medication: 2005–2011. <i>Journal of Asthma</i> , 2018, 55, 907-914.	1.7	1
74	Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 263-271.	1.9	16
75	Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug–outcome associations: The case of clindamycin and <i>Clostridium difficile</i> infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 731-739.	1.9	6
76	Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer’s Capture of Spontaneous Reports for Exposed Pregnancies. <i>Drug Safety</i> , 2018, 41, 87-94.	3.2	18
77	Safety assessment of niacin in the US Food and Drug Administration’s mini-sentinel system. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 30-37.	1.9	10
78	Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. <i>Diabetes Care</i> , 2018, 41, 39-48.	8.6	21
79	A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system. <i>Genetics in Medicine</i> , 2018, 20, 390-396.	2.4	20
80	A Query Workflow Design to Perform Automatable Distributed Regression Analysis in Large Distributed Data Networks. <i>EGEMS (Washington, DC)</i> , 2018, 6, 11.	2.0	16
81	Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss. <i>Annals of Internal Medicine</i> , 2018, 169, 741.	3.9	210
82	Validation of the Combined Comorbidity Index of Charlson and Elixhauser to Predict 30-Day Mortality Across ICD-9 and ICD-10. <i>Medical Care</i> , 2018, 56, 812-812.	2.4	19
83	Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 505-508.	1.4	7
84	Comparison of privacy-protecting analytic and data-sharing methods: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1034-1041.	1.9	13
85	Overall and cause-specific mortality in the Sentinel system: A power analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1416-1421.	1.9	2
86	Combining distributed regression and propensity scores: a doubly privacy-protecting analytic method for multicenter research. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1773-1786.	3.0	13
87	Using Machine Learning to Identify Health Outcomes from Electronic Health Record Data. <i>Current Epidemiology Reports</i> , 2018, 5, 331-342.	2.4	56
88	Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives. <i>JAMA Internal Medicine</i> , 2018, 178, 1482.	5.1	10
89	Early Antibiotic Exposure and Weight Outcomes in Young Children. <i>Pediatrics</i> , 2018, 142, .	2.1	59
90	Assessing the impact of the new ICD–10–CM coding system on pharmacoepidemiologic studies—An application to the known association between angiotensin-converting enzyme inhibitors and angioedema. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 829-838.	1.9	6

#	ARTICLE	IF	CITATIONS
91	Evaluating automated approaches to anaphylaxis case classification using unstructured data from the FDA Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1077-1084.	1.9	17
92	Early impact of the ICD-10-CM transition on selected health outcomes in 13 electronic health care databases in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 839-847.	1.9	44
93	Outpatient influenza antivirals in a distributed data network for influenza surveillance. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 804-807.	3.4	8
94	Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. <i>American Journal of Epidemiology</i> , 2018, 187, 2439-2448.	3.4	8
95	Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 1374-1386.	1.2	71
96	Accuracy of Electronic Health Record-Derived Data for the Identification of Incident ADHD. <i>Journal of Attention Disorders</i> , 2017, 21, 416-425.	2.6	17
97	Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 592-596.	1.9	47
98	Estimating Effects of Dynamic Treatment Strategies in Pharmacoepidemiologic Studies with Time-Varying Confounding: a Primer. <i>Current Epidemiology Reports</i> , 2017, 4, 288-297.	2.4	17
99	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1018-1032.	1.9	126
100	Trends in 30-day readmission rates after COPD hospitalization, 2006-2012. <i>Respiratory Medicine</i> , 2017, 130, 92-97.	2.9	44
101	Pharmacoepidemiology in the Era of Real-World Evidence. <i>Current Epidemiology Reports</i> , 2017, 4, 262-265.	2.4	6
102	Stakeholders' views on data sharing in multicenter studies. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 537-547.	1.4	36
103	Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. <i>Medical Care</i> , 2017, 55, 1046-1051.	2.4	67
104	Sentinel Modular Program for Propensity Score-Matched Cohort Analyses. <i>Epidemiology</i> , 2017, 28, 838-846.	2.7	32
105	Administrative Claims Data Versus Augmented Pregnancy Data for the Study of Pharmaceutical Treatments in Pregnancy. <i>Current Epidemiology Reports</i> , 2017, 4, 106-116.	2.4	30
106	Development and Application of Two Semi-Automated Tools for Targeted Medical Product Surveillance in a Distributed Data Network. <i>Current Epidemiology Reports</i> , 2017, 4, 298-306.	2.4	16
107	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice. <i>Annals of Internal Medicine</i> , 2017, 167, 845.	3.9	37
108	The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics. <i>JMIR Research Protocols</i> , 2017, 6, e222.	1.0	37

#	ARTICLE	IF	CITATIONS
109	Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1023-1032.	1.9	6
110	Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 170-178.	1.9	27
111	National Trends in Outpatient Antihypertensive Prescribing in People with Dementia in the United States. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1425-1435.	2.6	4
112	4.16 HEART FAILURE AND CARDIOMYOPATHY FOLLOWING INITIATION OF MEDICATIONS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S168.	0.5	0
113	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs. <i>Annals of Internal Medicine</i> , 2016, 164, 705.	3.9	91
114	Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β_2 -agonist regulation from 2005-2011. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 710-717.	2.9	17
115	Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program. <i>Archives of Women's Mental Health</i> , 2016, 19, 969-977.	2.6	42
116	Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program. <i>Maternal and Child Health Journal</i> , 2016, 20, 895-903.	1.5	31
117	Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 973-981.	1.9	22
118	Guidelines for good pharmacoepidemiology practice (GPP). <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 2-10.	1.9	164
119	Network Meta-Analysis Using Observational Data From Distributed Health Data Networks: A Conceptual Framework And Illustrative Example. <i>Value in Health</i> , 2016, 19, A108.	0.3	0
120	Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 558-564.	4.7	33
121	Sulfonamide Use During the First Trimester of Pregnancy and Risk of Selected Congenital Anomalies Among Live Births. <i>Journal of Patient-centered Research and Reviews</i> , 2016, 3, 202-203.	0.9	0
122	Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. <i>Systematic Reviews</i> , 2015, 4, 147.	5.3	99
123	Potential Bias of Instrumental Variable Analyses for Observational Comparative Effectiveness Research. <i>Annals of Internal Medicine</i> , 2014, 161, 131.	3.9	103
124	Response to the letter by Mol. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 106-106.	1.9	0
125	RE: Drug risk assessment and data reuse. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 109-110.	1.9	0
126	Privacy-preserving Analytic Methods for Multisite Comparative Effectiveness and Patient-centered Outcomes Research. <i>Medical Care</i> , 2014, 52, 664-668.	2.4	28

#	ARTICLE	IF	CITATIONS
127	Comparative Effectiveness of Laparoscopic Adjustable Gastric Banding vs Laparoscopic Gastric Bypass. <i>JAMA Surgery</i> , 2014, 149, 1279.	4.3	28
128	The Prevalence and Trends of Antiviral Medication Use During Pregnancy in the US: A Population-Based Study of 664,297 Deliveries in 2001–2007. <i>Maternal and Child Health Journal</i> , 2014, 18, 64-72.	1.5	8
129	Pharmacotherapy for incident attention-deficit/hyperactivity disorder: practice patterns and quality metrics. <i>Current Medical Research and Opinion</i> , 2014, 30, 1687-1699.	1.9	10
130	Trends in Elective Labor Induction for Six United States Health Plans, 2001–2007. <i>Journal of Women's Health</i> , 2014, 23, 904-911.	3.3	20
131	Chronic opioid use emerging after bariatric surgery. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1247-1257.	1.9	69
132	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 1223-1225.	1.9	4
133	Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 40-54.	1.9	71
134	Validity of health plan and birth certificate data for pregnancy research. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 7-15.	1.9	114
135	Medication Exposure in Pregnancy Risk Evaluation Program: The Prevalence of Asthma Medication Use During Pregnancy. <i>Maternal and Child Health Journal</i> , 2013, 17, 1611-1621.	1.5	44
136	Validation of an algorithm to estimate gestational age in electronic health plan databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 524-532.	1.9	87
137	An Analytic Framework for Aligning Observational and Randomized Trial Data: Application to Postmenopausal Hormone Therapy and Coronary Heart Disease. <i>Statistics in Biosciences</i> , 2013, 5, 344-360.	1.2	13
138	Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001–2007: a population-based study of 585,615 deliveries. <i>Archives of Women's Mental Health</i> , 2013, 16, 149-157.	2.6	107
139	Is Size the Next Big Thing in Epidemiology?. <i>Epidemiology</i> , 2013, 24, 349-351.	2.7	34
140	A critical review of methods to evaluate the impact of FDA regulatory actions. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 986-994.	1.9	66
141	Multivariable confounding adjustment in distributed data networks without sharing of patient-level data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1171-1177.	1.9	32
142	Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1239-1244.	1.9	21
143	Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 861-872.	1.9	46
144	Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 776-782.	1.9	21

#	ARTICLE	IF	CITATIONS
145	Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1036-1045.	1.9	11
146	Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program. <i>JAMA Internal Medicine</i> , 2013, 173, 817.	5.1	24
147	Prevalence, Trends, and Patterns of Use of Antidiabetic Medications Among Pregnant Women, 2001-2007. <i>Obstetrics and Gynecology</i> , 2013, 121, 106-114.	2.4	22
148	Confounding Adjustment in Comparative Effectiveness Research Conducted Within Distributed Research Networks. <i>Medical Care</i> , 2013, 51, S4-S10.	2.4	55
149	Data Quality Assessment for Comparative Effectiveness Research in Distributed Data Networks. <i>Medical Care</i> , 2013, 51, S22-S29.	2.4	112
150	Big Data in Epidemiology. <i>Epidemiology</i> , 2013, 24, 939.	2.7	11
151	Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System. <i>Archives of Internal Medicine</i> , 2012, 172, 1582.	3.8	178
152	PCV12 Determinants of Exposure to Potential Interactions Between Antiplatelet Drugs, Anticoagulants, Digoxin and Common Chinese Medications in Taiwan. <i>Value in Health</i> , 2012, 15, A631.	0.3	0
153	Trends in the Use of Antiepileptic Drugs among Pregnant Women in the US, 2001-2007: A Medication Exposure in Pregnancy Risk Evaluation Program Study. <i>Paediatric and Perinatal Epidemiology</i> , 2012, 26, 578-588.	1.7	68
154	Medication Exposure in Pregnancy Risk Evaluation Program. <i>Maternal and Child Health Journal</i> , 2012, 16, 1349-1354.	1.5	57
155	Design for validation of acute myocardial infarction cases in Mini-Sentinel. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 274-281.	1.9	33
156	Design considerations in an active medical product safety monitoring system. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 32-40.	1.9	46
157	A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 282-290.	1.9	34
158	The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1-8.	1.9	155
159	Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 524-534.	1.9	30
160	Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 13-20.	1.9	28
161	Antibiotics and oral contraceptive failure - a case-crossover study. <i>Contraception</i> , 2011, 83, 418-425.	1.5	37
162	National Trends in Prescribing Antidepressants Before and After an FDA Advisory on Suicidality Risk in Youths. <i>Psychiatric Services</i> , 2011, 62, 727-733.	2.0	9

#	ARTICLE	IF	CITATIONS
163	Comparative-Effectiveness Research in Distributed Health Data Networks. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 883-887.	4.7	62
164	Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 849-857.	1.9	75
165	Validation of algorithms to ascertain clinical conditions and medical procedures used during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1168-1176.	1.9	29
166	Letter in response to Schneeweiss and Rassen on the high-dimensional propensity score approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1112-1112.	1.9	0
167	Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study. <i>PLoS ONE</i> , 2011, 6, e21368.	2.5	49
168	Estimating Absolute Risks in the Presence of Nonadherence. <i>Epidemiology</i> , 2010, 21, 528-539.	2.7	57
169	Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?. <i>Annals of Internal Medicine</i> , 2010, 152, 211.	3.9	97
170	PMH87 NATIONAL TRENDS IN PRESCRIBING ANTIDEPRESSANTS FOR DEPRESSION – BEFORE AND AFTER FDA ADVISORY ON RISK OF SUICIDALITY AMONG CHILDREN AND ADOLESCENTS. <i>Value in Health</i> , 2010, 13, A121.	0.3	0
171	Menopausal Hormone Therapy and Risk for Cardiovascular Disease in the WHI Trial. <i>Annals of Internal Medicine</i> , 2010, 153, 61.	3.9	0
172	Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. <i>BMJ</i> , The, 2009, 338, b2255-b2255.	6.0	404
173	Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension. <i>American Journal of Psychiatry</i> , 2009, 166, 320-328.	7.2	89
174	Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 555-560.	1.4	70
175	Causal Inference from Longitudinal Studies with Baseline Randomization. <i>International Journal of Biostatistics</i> , 2008, 4, Article 22.	0.7	88
176	Sensitivity and Specificity of Computerized Algorithms to Classify Gestational Periods in the Absence of Information on Date of Conception. <i>American Journal of Epidemiology</i> , 2007, 167, 633-640.	3.4	63
177	Toh et al. Respond to "Compromise or Compromising?". <i>American Journal of Epidemiology</i> , 2007, 167, 644-645.	3.4	1
178	Statins and fracture risk. A systematic review. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 627-640.	1.9	75
179	Use of antidepressants and risk of lung cancer. <i>Cancer Causes and Control</i> , 2007, 18, 1055-1064.	1.8	33
180	MH1 NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND USE OF STIMULANTS AMONG CHILDREN IN THE UNITED STATES, 1993-2003. <i>Value in Health</i> , 2006, 9, A15.	0.3	0

#	ARTICLE	IF	CITATIONS
181	PMH16 HEALTH CARE COSTS AND UTILIZATION PATTERNS OF INDIVIDUALS WITH GENERALIZED ANXIETY DISORDER (GAD) IN THE UNITED STATES. <i>Value in Health</i> , 2006, 9, A69.	0.3	0
182	Datapoints: Trends in ADHD and Stimulant Use Among Children, 1993-2003. <i>Psychiatric Services</i> , 2006, 57, 1091-1091.	2.0	18
183	Frequency estimates from prescription drug datasets (revision of #04-11-066A). <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 512-520.	1.9	7
184	Datapoints: Trends in ADHD and Stimulant Use Among Children, 1993-2003. <i>Psychiatric Services</i> , 2006, 57, 1091-1091.	2.0	5
185	Go BIG and Go Global: Executing Large-Scale, Multi-Site Pharmacoepidemiologic Studies Using Real-world Data. <i>American Journal of Epidemiology</i> , 0, , .	3.4	1